Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + TORL-1-23 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| TORL-1-23 | TORL 1-23|TORL1-23|CLDN6-23-ADC|TORL123 | CLDN6 Antibody 10 | TORL-1-23 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN6 linked to monomethyl auristatin E (MMAE), which potentially inhibits growth of CLDN6-expressing tumors (PMID: 36884217). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07322094 | Phase Ib/II | Carboplatin + Paclitaxel + TORL-1-23 Paclitaxel + TORL-1-23 Carboplatin + TORL-1-23 | CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer | Recruiting | USA | 0 |